Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients

BACKGROUND: Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Therefore we aimed to use a blood-based protein signature (V...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Cell Int
Auteurs principaux: Jia, Bo, Dong, Zhi, Wu, Di, Zhao, Jun, Wu, Meina, An, Tongtong, Wang, Yuyan, Zhuo, Minglei, Li, Jianjie, Wang, Yang, Zhang, Jie, Zhao, Xinghui, Li, Sheng, Li, Junfeng, Ma, Menglei, Chen, Chen, Yang, Xue, Zhong, Jia, Chen, Hanxiao, Wang, Jingjing, Chi, Yujia, Zhai, Xiaoyu, Cui, Song, Zhang, Rong, Ma, Qingwei, Fang, Jian, Wang, Ziping
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2020
Sujets:
Primary Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724790/
https://ncbi.nlm.nih.gov/pubmed/33298069
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-020-01662-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires